Skip to content

Gut-linked microbes tied to survival in DLBCL
Latest COMMANDS analysis shows luspatercept is transformative in MDS
Idoroenyi Amanam, MD, discusses real-world study of luspatercept in LR-MDS
‘Boom Boom Radiotherapy’ approach may boost CAR T-cell responses
B-ALL patients refractory to brexu-cel face poor survival outcomes

Join SOHO

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Multiple Myeloma News

FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma

by Leah Sherwood
May 22, 2025
0 Comments

Multiple Myeloma

New genomic test provides a less invasive option for myeloma diagnosis

by sohonews
April 30, 2025
0 Comments

Cellular Therapy 2025 AACR Annual Meeting Multiple Myeloma

Trispecific therapy ISB 2001 active in ongoing early myeloma trial

by Leah Sherwood
April 29, 2025
0 Comments

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.

Multiple Myeloma News

Early intervention with daratumumab for smoldering myeloma may delay disease progression

by SOHO Insider Editors
April 25, 2025
0 Comments

Multiple Myeloma News

Real-world data support efficacy of IsaPd triplet in relapsed/refractory myeloma

by SOHO Insider Editors
April 22, 2025
0 Comments

Lymphoma Multiple Myeloma News

Spain’s POC manufacturing model reimagines CAR-T delivery

by Leah Sherwood
April 20, 2025
0 Comments

Multiple Myeloma News

ISAF approves equecabtagene autoleucel for relapsed or refractory multiple myeloma

by SOHO Insider Editors
April 10, 2025
0 Comments

2025 EBMT Annual Meeting Multiple Myeloma News

CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma

by SOHO Insider Editors
April 9, 2025
0 Comments

Multiple Myeloma

Dr. Lipof discusses Myeloma Action Month

by Leah Sherwood
March 30, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma News

Is it time to revisit MRD’s role in relapse detection?

by SOHO Insider Editors
March 25, 2025
0 Comments

1
2
3

Top Categories

Cellular Therapy

12

Leukemia

41

Lymphoma

40

Multiple Myeloma

28

Myelodysplastic Syndromes

13

Myeloproliferative Neoplasms

9

POPULAR NEWS

Leukemia , Lymphoma , Multiple Myeloma , Myelodysplastic Syndromes , Myeloproliferative Neoplasms , News , Society Updates

Abstract submissions now open for SOHO 2025

February 14, 2025

Leukemia , Acute Myeloid Leukemia , Myelodysplastic Syndromes

NCI’s myeloMATCH pushes the envelope in myeloid leukemia care

January 3, 2025

66th American Society of Hematology Annual Meeting & Exposition , Leukemia

Asciminib benefit-risk profile bests other TKIs in CML

December 10, 2024

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Multiple Myeloma News

FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma

New genomic test provides a less invasive option for myeloma diagnosis

Trispecific therapy ISB 2001 active in ongoing early myeloma trial

Early intervention with daratumumab for smoldering myeloma may delay disease progression

Real-world data support efficacy of IsaPd triplet in relapsed/refractory myeloma

Spain’s POC manufacturing model reimagines CAR-T delivery

ISAF approves equecabtagene autoleucel for relapsed or refractory multiple myeloma

CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma

Dr. Lipof discusses Myeloma Action Month

Is it time to revisit MRD’s role in relapse detection?

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Gut-linked microbes tied to survival in DLBCL

Latest COMMANDS analysis shows luspatercept is transformative in MDS

Idoroenyi Amanam, MD, discusses real-world study of luspatercept in LR-MDS

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Multiple Myeloma News

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms